First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors

First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors

Abstract Background Transient CD4+ T cell depletion led to the proliferation of tumor-specific CD8+ T cells in the draining lymph node and increased infiltration of PD-1+CD8+ T cells into the tumor, which resulted in strong anti-tumor effects in tumor-bearing mice. This is a first-in-human study of...

Full description

Bibliographic Details
Main Authors: Kohei Shitara, Satoshi Ueha, Shigeyuki Shichino, Hiroyasu Aoki, Haru Ogiwara, Tetsuya Nakatsura, Toshihiro Suzuki, Manami Shimomura, Toshiaki Yoshikawa, Kayoko Shoda, Shigehisa Kitano, Makiko Yamashita, Takayuki Nakayama, Akihiro Sato, Sakiko Kuroda, Masashi Wakabayashi, Shogo Nomura, Shoji Yokochi, Satoru Ito, Kouji Matsushima, Toshihiko Doi
Format: Article
Language:English
Published: BMJ Publishing Group 2019-07-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Anti-CD4 antibody
CD4+ T cells
CD8+ T cells
Immunotherapy
Online Access:http://link.springer.com/article/10.1186/s40425-019-0677-y

Internet

http://link.springer.com/article/10.1186/s40425-019-0677-y

Similar Items